News
03-22-2009, 05:01 AM
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that a multicenter Phase 3 study of Lymphoseek® has reached the accrual of 203 lymph nodes, the study's primary accrual objective. The multi-center open label study has been conducted in patients with either breast cancer or melanoma.
More... (http://www.medicalnewstoday.com/articles/143138.php)
More... (http://www.medicalnewstoday.com/articles/143138.php)